Image courtesy of Philips Healthcare
2020年1月27日至今According to the new market research report "Nuclear Medicine Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024", published byMarketsandMarkets, thenuclear medicinemarket is expected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, at a CAGR of 4.7 percent.
The key factors driving the growth of this radiopharmaceuticals market are increasing incidence and prevalence of cancer and cardiac ailments, and initiatives to lessen the demand-supply gap ofMo-99.
SPECT radiopharmaceuticals segment expected to account for the largest share
Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The diagnostic nuclear medicine segment is further categorized intoSPECTandPETradiopharmaceuticals. The SPECT radiopharmaceuticals segment is expected to account for the largest share of the market in 2019. However, the PET radiopharmaceutical segment is projected to register the highest CAGR during the forecast period. Although PET is more expensive than SPECT, advances in PET imaging and the introduction of new PET radiotracers are supporting its growth in the market.
North America to dominate the market in 2019
北美、欧洲、亚太和世界其他地区(RoW)是全球核医学市场研究的地理分析区域。预计北美将占全球核医学产业的最大份额。北美市场的增长可以归因于放射性同位素生产新技术的发展、政府资助和该地区公司的举措。
For more information:www.marketsandmarkets.com
August 10, 2022
